Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.
Kappel-Latif S, Zacherl J, Hejna M, Westerhoff M, Tamandl D, Ba-Ssalamah A, Mittlböck M, Wolf B, Wrba F, Kührer I, Pluschnig U, Schoppmann SF, Függer R, Zwrtek R, Glaser K, Karner J, Längle F, Wenzl E, Roka R, Öfner D, Tschmelitsch J, Hold M, Keil F, Gnant M, Kandioler D; Pancho trialists and for the Medical University of Vienna p53research group. Kappel-Latif S, et al. Among authors: pluschnig u. Eur Surg. 2018;50(4):160-166. doi: 10.1007/s10353-018-0527-z. Epub 2018 Jun 11. Eur Surg. 2018. PMID: 30559831 Free PMC article.
Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.
Spizzo G, Öfner D, de Vries A, Lukas P, Steger G, Pluschnig U, Zacherl J, Widder J, Zabernigg A, Gastl G, Mühlmann G. Spizzo G, et al. Among authors: pluschnig u. Ann Surg Oncol. 2011 Mar;18(3):677-83. doi: 10.1245/s10434-010-1388-2. Epub 2010 Nov 10. Ann Surg Oncol. 2011. PMID: 21063792 Clinical Trial.
Brain metastases free survival differs between breast cancer subtypes.
Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R. Berghoff A, et al. Among authors: pluschnig u. Br J Cancer. 2012 Jan 31;106(3):440-6. doi: 10.1038/bjc.2011.597. Epub 2012 Jan 10. Br J Cancer. 2012. PMID: 22233926 Free PMC article.
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.
Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG. Bartsch R, et al. Among authors: pluschnig u. Br J Cancer. 2012 Jan 3;106(1):25-31. doi: 10.1038/bjc.2011.531. Epub 2011 Nov 29. Br J Cancer. 2012. PMID: 22127284 Free PMC article.
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R. Michlmayr A, et al. Among authors: pluschnig u. Br J Cancer. 2010 Oct 12;103(8):1201-8. doi: 10.1038/sj.bjc.6605909. Epub 2010 Sep 28. Br J Cancer. 2010. PMID: 20877360 Free PMC article. Clinical Trial.
Combined contrast-enhanced magnetic resonance and diffusion-weighted imaging reading adapted to the "Breast Imaging Reporting and Data System" for multiparametric 3-T imaging of breast lesions.
Pinker K, Bickel H, Helbich TH, Gruber S, Dubsky P, Pluschnig U, Rudas M, Bago-Horvath Z, Weber M, Trattnig S, Bogner W. Pinker K, et al. Among authors: pluschnig u. Eur Radiol. 2013 Jul;23(7):1791-802. doi: 10.1007/s00330-013-2771-8. Epub 2013 Mar 16. Eur Radiol. 2013. PMID: 23504036
Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial.
Schmidinger M, Budinsky AC, Wenzel C, Locker GJ, Pluschnig U, Brodowicz T, Kubista E, Maca S, Zabernigg A, Ilsinger P, Seewann L, Hojas S, Blach M, Zielinski CC, Steger GG. Schmidinger M, et al. Among authors: pluschnig u. Cancer Chemother Pharmacol. 2001;47(1):57-62. doi: 10.1007/s002800000204. Cancer Chemother Pharmacol. 2001. PMID: 11221963
64 results